Literature DB >> 24497562

High XBP1 expression is a marker of better outcome in multiple myeloma patients treated with bortezomib.

Manuela Gambella1, Alberto Rocci, Roberto Passera, Francesca Gay, Paola Omedè, Claudia Crippa, Paolo Corradini, Alessandra Romano, Davide Rossi, Marco Ladetto, Mario Boccadoro, Antonio Palumbo.   

Abstract

Entities:  

Keywords:  BLIMP1; IRF4; XBP1; bortezomib; multiple myeloma biomarker

Mesh：

Substances：

Year:  2014        PMID： 24497562      PMCID： PMC3912976          DOI： 10.3324/haematol.2013.090142

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  10 in total

1.  Plasma cell differentiation requires the transcription factor XBP-1.

Authors:  A M Reimold; N N Iwakoshi; J Manis; P Vallabhajosyula; E Szomolanyi-Tsuda; E M Gravallese; D Friend; M J Grusby; F Alt; L H Glimcher
Journal:  Nature       Date:  2001-07-19       Impact factor: 49.962

2.  Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma.

Authors:  D Heintel; N Zojer; M Schreder; K Strasser-Weippl; B Kainz; M Vesely; H Gisslinger; J Drach; A Gaiger; U Jäger; H Ludwig
Journal:  Leukemia       Date:  2007-08-09       Impact factor: 11.528

3.  Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response.

Authors:  Antonia Lopez-Girona; Daniel Heintel; Ling-Hua Zhang; Derek Mendy; Svetlana Gaidarova; Helen Brady; Justin Blake Bartlett; Peter H Schafer; Martin Schreder; Arnold Bolomsky; Bernadette Hilgarth; Niklas Zojer; Heinz Gisslinger; Heinz Ludwig; Tom Daniel; Ulrich Jäger; Rajesh Chopra
Journal:  Br J Haematol       Date:  2011-06-24       Impact factor: 6.998

4.  XBP1s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments.

Authors:  Tina Bagratuni; Ping Wu; David Gonzalez de Castro; Emma L Davenport; Nicholas J Dickens; Brian A Walker; Kevin Boyd; David C Johnson; Walter Gregory; Gareth J Morgan; Faith E Davies
Journal:  Blood       Date:  2010-04-26       Impact factor: 22.113

5.  International uniform response criteria for multiple myeloma.

Authors:  B G M Durie; J-L Harousseau; J S Miguel; J Bladé; B Barlogie; K Anderson; M Gertz; M Dimopoulos; J Westin; P Sonneveld; H Ludwig; G Gahrton; M Beksac; J Crowley; A Belch; M Boccadaro; M Cavo; I Turesson; D Joshua; D Vesole; R Kyle; R Alexanian; G Tricot; M Attal; G Merlini; R Powles; P Richardson; K Shimizu; P Tosi; G Morgan; S V Rajkumar
Journal:  Leukemia       Date:  2006-07-20       Impact factor: 11.528

6.  Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination.

Authors:  Ulf Klein; Stefano Casola; Giorgio Cattoretti; Qiong Shen; Marie Lia; Tongwei Mo; Thomas Ludwig; Klaus Rajewsky; Riccardo Dalla-Favera
Journal:  Nat Immunol       Date:  2006-06-11       Impact factor: 25.606

7.  Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

Authors:  Silke Meister; Ulrich Schubert; Kirsten Neubert; Kai Herrmann; Renate Burger; Martin Gramatzki; Sabine Hahn; Sandra Schreiber; Sabine Wilhelm; Martin Herrmann; Hans-Martin Jäck; Reinhard E Voll
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

8.  Response of myeloma to the proteasome inhibitor bortezomib is correlated with the unfolded protein response regulator XBP-1.

Authors:  Silvia C W Ling; Edwin K K Lau; Ammira Al-Shabeeb; Angela Nikolic; Albert Catalano; Harry Iland; Noemi Horvath; P Joy Ho; Simon Harrison; Shaun Fleming; Douglas E Joshua; John D Allen
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

9.  Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.

Authors:  Antonio Palumbo; Sara Bringhen; Davide Rossi; Maide Cavalli; Alessandra Larocca; Roberto Ria; Massimo Offidani; Francesca Patriarca; Chiara Nozzoli; Tommasina Guglielmelli; Giulia Benevolo; Vincenzo Callea; Luca Baldini; Fortunato Morabito; Mariella Grasso; Giovanna Leonardi; Manuela Rizzo; Antonietta Pia Falcone; Daniela Gottardi; Vittorio Montefusco; Pellegrino Musto; Maria Teresa Petrucci; Giovannino Ciccone; Mario Boccadoro
Journal:  J Clin Oncol       Date:  2010-10-12       Impact factor: 44.544

10.  Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients.

Authors:  Antonio Palumbo; Francesca Gay; Patrizia Falco; Claudia Crippa; Vittorio Montefusco; Francesca Patriarca; Fausto Rossini; Simona Caltagirone; Giulia Benevolo; Norbert Pescosta; Tommasina Guglielmelli; Sara Bringhen; Massimo Offidani; Nicola Giuliani; Maria Teresa Petrucci; Pellegrino Musto; Anna Marina Liberati; Giuseppe Rossi; Paolo Corradini; Mario Boccadoro
Journal:  J Clin Oncol       Date:  2010-01-04       Impact factor: 44.544
  10 in total
  24 in total

Review 1.  Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma.

Authors:  Masaki Ri
Journal:  Int J Hematol       Date:  2016-05-12       Impact factor: 2.490

Review 2.  Metabolic Control of Plasma Cell Differentiation- What We Know and What We Don't Know.

Authors:  Michael Aronov; Boaz Tirosh
Journal:  J Clin Immunol       Date:  2016-02-24       Impact factor: 8.317

Review 3.  Targeting the unfolded protein response in head and neck and oral cavity cancers.

Authors:  Daniel W Cole; Peter F Svider; Kerolos G Shenouda; Paul B Lee; Nicholas G Yoo; Thomas M McLeod; Sean A Mutchnick; George H Yoo; Randal J Kaufman; Michael U Callaghan; Andrew M Fribley
Journal:  Exp Cell Res       Date:  2019-05-07       Impact factor: 3.905

Review 4.  Novel therapeutic strategies for multiple myeloma.

Authors:  Naoya Mimura; Teru Hideshima; Kenneth C Anderson
Journal:  Exp Hematol       Date:  2015-06-26       Impact factor: 3.084

5.  Plasma cell maturity as a predictor of prognosis in multiple myeloma.

Authors:  Noriyoshi Iriyama; Katsuhiro Miura; Yoshihiro Hatta; Yoshihito Uchino; Daisuke Kurita; Hiromichi Takahashi; Hitomi Sakagami; Masashi Sakagami; Yujin Kobayashi; Masaru Nakagawa; Shimon Ohtake; Yoshikazu Iizuka; Masami Takei
Journal:  Med Oncol       Date:  2016-07-06       Impact factor: 3.064

6.  Bortezomib- and carfilzomib-resistant myeloma cells show increased activity of all three arms of the unfolded protein response.

Authors:  Tadeusz Kubicki; Kinga Bednarek; Magdalena Kostrzewska-Poczekaj; Magdalena Luczak; Krzysztof Lewandowski; Lidia Gil; Malgorzata Jarmuz-Szymczak; Dominik Dytfeld
Journal:  Am J Cancer Res       Date:  2022-07-15       Impact factor: 5.942

Review 7.  IRE1α Inhibitors as a Promising Therapeutic Strategy in Blood Malignancies.

Authors:  Wojciech Wiese; Natalia Siwecka; Adam Wawrzynkiewicz; Wioletta Rozpędek-Kamińska; Ewa Kucharska; Ireneusz Majsterek
Journal:  Cancers (Basel)       Date:  2022-05-20       Impact factor: 6.575

Review 8.  Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma.

Authors:  Sinan Xiong; Wee-Joo Chng; Jianbiao Zhou
Journal:  Cell Mol Life Sci       Date:  2021-02-18       Impact factor: 9.261

9.  Interplay between unfolded protein response and autophagy promotes tumor drug resistance.

Authors:  Ming-Ming Yan; Jiang-Dong Ni; Deye Song; Muliang Ding; Jun Huang
Journal:  Oncol Lett       Date:  2015-07-17       Impact factor: 2.967

10.  Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells.

Authors:  Wenwen Chien; Ling-Wen Ding; Qiao-Yang Sun; Lucia A Torres-Fernandez; Siew Zhuan Tan; Jinfen Xiao; Su Lin Lim; Manoj Garg; Kian Leong Lee; Shojiro Kitajima; Sumiko Takao; Wei Zhong Leong; Haibo Sun; Itay Tokatly; Lorenz Poellinger; Sigal Gery; Phillip H Koeffler
Journal:  Oncotarget       Date:  2014-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.